Cargando…
First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism
Capecitabine, an oral prodrug of 5-FU, has been approved by the FDA for use in patients with breast and colon cancers. In addition, capecitabine is commonly used in patients with other malignancies such as pancreatic, gastroesophageal, and hepatobiliary tract cancers. Though cerebellar toxicity is a...
Autores principales: | Wilks, Andrew B, Saif, Muhammad W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325748/ https://www.ncbi.nlm.nih.gov/pubmed/28280649 http://dx.doi.org/10.7759/cureus.995 |
Ejemplares similares
-
The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016) -
Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?
por: Saif, Muhammad W, et al.
Publicado: (2016) -
Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism
por: Wang, Bo, et al.
Publicado: (2016) -
Non-covalent interactions involving halogenated derivatives of capecitabine and thymidylate synthase: a computational approach
por: Rahman, Adhip, et al.
Publicado: (2016) -
Effect of Hammerhead Ribozyme against Human Thymidylate Synthase on the Cytotoxicity of Thymidylate Synthase Inhibitors
por: Kobayashi, Hiroyuki, et al.
Publicado: (1995)